The EU Council has published a comprehensive health threat assessment identifying priority pathogens to guide the development and deployment of medical countermeasures (MCMs) such as vaccines and therapeutics. The document, released on 1 September 2026, aims to strengthen EU preparedness and response to serious cross-border health threats by prioritising actions for MCM development, production, and stockpiling.
The assessment, produced under the Council's health security framework, identifies viral families of highest priority, including Coronaviridae, Orthomyxoviridae (influenza), Flaviviridae (e.g., West Nile, Zika), Filoviridae (Ebola), and Poxviridae (Mpox). It also addresses antimicrobial resistance (AMR) and CBRN threats. This work directly supports the implementation of the EU's MCM Strategy and falls within the core policy area of health security and emergency preparedness, led by the Health Emergency Preparedness and Response Authority (HERA).
Policy orientations and trade-offs The assessment represents a strategic orientation rather than binding legislation, providing a scientific basis for future EU investment in MCM research, procurement, and stockpiling. By focusing on specific pathogen families, the EU aims to allocate resources efficiently, but this prioritisation may leave other emerging threats underfunded. The inclusion of AMR and CBRN threats broadens the scope beyond infectious diseases, reflecting a comprehensive approach to health security.
Impact on stakeholders - EU regulatory bodies (HERA, EMA): The list will guide HERA's work on MCM procurement and stockpiling, and the European Medicines Agency may use it to prioritise regulatory pathways for vaccines and treatments. - Pharmaceutical and biotech industry: Companies developing MCMs for listed pathogens may benefit from EU funding and streamlined regulatory processes, but those working on non-priority pathogens could face reduced support. - National health authorities: Member states may align their national preparedness plans with the EU list, potentially improving cross-border coordination but also imposing administrative burdens to update stockpiles. - EU citizens: The prioritisation aims to ensure faster access to MCMs during future outbreaks, but the focus on specific pathogens may leave gaps in protection against unforeseen threats.
Expected institutional follow-up The Council's assessment will inform HERA's upcoming work programme and the implementation of the MCM Strategy. The European Commission is expected to propose concrete funding allocations and procurement plans based on the list. The European Parliament may hold hearings to scrutinise the prioritisation criteria and ensure transparency. Member states will be invited to integrate the list into their national preparedness plans, with a review expected within two years.
← Atlas › News › Health & Lifestyle